Aims/hypothesis Anaemia is a common complication of renal impairment.
Introduction
WHO estimates that there will be 221 million diabetic patients worldwide by 2010, rising from an estimated 151 million in 2000 [1] . Diabetes continues to be the most common cause for end-stage renal disease in the western world [2] [3] [4] . The increasing incidence of diabetes and improved longevity due to better management of such patients is likely to further increase the workload for diabetologists and nephrologists from this disease group. Patients with diabetic kidney disease continue to have a poor prognosis, with mortality being 70 to 100 times that of a matched population [5] . The excess cardiovascular mortality associated with diabetes and chronic renal failure is well recognised [6] .
Anaemia is one of many modifiable factors that influence the morbidity and mortality associated with renal impairment. A common perception within the renal and diabetic community is that anaemia associated with diabetic kidney disease tends to be more severe when compared with anaemia in patients who have other causes of renal impairment. Preview of medical literature does not substantiate this conclusively, hence we set out to test this hypothesis formally in a large UK renal unit. A definitive answer to this question is especially relevant, because if the perception is confirmed, effective and proven treatment in the form of recombinant human erythropoietin is already available.
Subjects and methods
Selection and classification of participants All ambulatory patients under active follow-up by the Richard Bright Renal Unit at Bristol, UK between 1 January 2004 and 31 June 2004 were assessed for inclusion. The renal unit is the regional nephrology referral centre with a catchment population of 1.3 million. The PROTON database used by the unit was interrogated for clinical and laboratory information and if required additional data were obtained from case notes. The data were collected retrospectively and none of the patients had blood tests performed solely for the purpose of inclusion in the study. Patients were included if they had a minimum of 6 months of follow-up and two or more estimations of renal and haematological parameters. Exclusion criteria included clinical history of recent blood loss, recent in-patient admission, current or previous history of cytotoxic therapy, current or previous erythropoietin therapy, current or recent intravenous iron therapy, recent history of blood transfusion, patients on renal replacement therapy, diagnosis of rapidly progressive glomerulonephritis, patients with acute renal failure and patients with current history of malignancy including haematological malignancies (Fig. 1 ).
Patients were classed as having diabetic nephropathy either by renal histology or if they had the full range of clinical features (including diabetic retinopathy, proteinuria, hypertension and drug controlled type 1 or 2 diabetes) associated with absence of any clinical features capable of providing an alternative explanation of renal impairment. Of the 336 patients categorised as having diabetic nephropathy, 29 patients had this proven by renal biopsy; in the remainder diagnosis was on the basis of the full range of clinical criteria. Patients with either (1) diabetes plus another cause for renal failure or (2) diabetic nephropathy with a second pathology as determined by renal histology were excluded from the analysis. All other patients with no current or previous history of diabetes (as defined by the WHO criteria) were included in the category of nondiabetic renal disease.
Glomerular filtration rate was estimated using the modified four variable Modification of Diet in Renal Disease formula [7] . Patients were grouped according to the National Kidney Federation/Disease Outcomes Quality Initiative Chronic Kidney Disease (CKD) stages 1 to 5 based on estimated GFR [8] . Current and prior drug history was evaluated from the database. Subjects were included as being on ACE inhibitor (ACEI) therapy if drugs from that class had been prescribed for a minimum of 3 months prior to their last recorded haemoglobin level. Length of followup was defined as time from original referral to the renal service. Even though two or more urine dipstick results were available for all patients, uniformly quantified data on proteinuria were not available and hence we were unable to analyse the influence of this variable on haemoglobin levels.
Statistical methods Data were analysed using GraphPad Prism for Windows version 4.0 (GraphPad Software, San Diego, CA, USA). After parameters were tested for 
Results
Baseline characteristics Patient characteristics are shown in Table 1 . As expected, there were considerably more patients with type 2 diabetes than type 1 diabetes in the diabetic nephropathy group. At all CKD stages, GFR in patients with diabetic and non-diabetic kidney disease was comparable. There was no significant difference in GFR between patients with type 1 and type 2 diabetes or upon individual comparison of each diabetes type with nondiabetic patients at all CKD stages (data not shown). The study population was predominantly (>97%) white, in keeping with the demographics of the region. There was no difference in ethnicity between the diabetic and nondiabetic groups of patients.
Haemoglobin levels Figure 2 denotes the linear regression analysis of haemoglobin (with 95% CI) against GFR in patients with diabetic vs those with non-diabetic kidney disease. The difference between the two slopes is statistically significant (p<0.01). Mean haemoglobin levels with 95% CI at each CKD stage for both groups of patients are listed in Table 2 . The haemoglobin levels in diabetic patients tended to be lower at CKD stage 2 than in nondiabetic patients, with significantly lower levels at GFR <60 ml/min. This relationship is sustained up to CKD stage 5 renal impairment. Although we observed a trend towards lower haemoglobin in diabetic stage 2 CKD patients, this was a relatively smaller group in comparison with the nondiabetic patients. These results should therefore be interpreted with caution. There is no internationally agreed threshold of haemoglobin level to define anaemia in patients with renal disease. However, most clinicians worldwide tend to react with investigations or interventions at a level of less than 110 g/l in such patients. Hence, we have presented data comparing numbers and percentages of diabetic and non-diabetic patients with haemoglobin <110 g/l at various stages of kidney disease in Table 3 .
Other characteristics affecting haemoglobin levels Table 4 shows the other recognised factors that influence haemoglobin levels in patients with renal impairment. Information on plasma intact parathyroid hormone (PtH) levels and We were unable to obtain the same information in a substantial number of patients from the other CKD groups. This is not unexpected, as routine surveillance for secondary complications of chronic renal impairment is undertaken only in patients with advanced renal impairment. Data on use of ACEIs and length of follow-up were available for all 2,052 patients, and no difference was found in either parameter between the diabetic and non-diabetic patients at all CKD stages (data not shown). As shown in Table 4 , in patients with GFR <30 ml/min there was no significant difference in ferritin levels, PtH levels, ACEI use or length of follow-up.
Discussion
The association between declining renal function and anaemia is well recognised [9] . The relationship between anaemia, diabetes and renal impairment has also been investigated in several small studies [10] [11] [12] . The Kidney Early Evaluation Study also reported diabetes to be independently correlated with anaemia in persons with moderate reduction in kidney function [13] . This study, however, is limited in as far as it was a targeted study with participant self-reporting being the major means of data gathering.
With regard to the question of whether anaemia in diabetic nephropathy is more severe than that seen in patients with non-diabetic kidney disease, two single centre studies with limited patient numbers have suggested that anaemia tends to occur earlier and is more severe in patients with diabetic nephropathy than in an equivalent non-diabetic patient group. Thus Bosman et al. [14] compared 27 patients with type 1 diabetes and diabetic nephropathy with 26 patients with glomerulonephritis. They reported that anaemia was more likely in diabetic patients and that serum erythropoietin levels were comparable in the two groups. This study included only patients with relatively well preserved renal function (creatinine <180 μmol/l). A similar study by Ishimura et al. [15] demonstrated that 19 patients with type 2 diabetes had comparable erythropoietin levels, but significantly lower haemoglobin when compared with 21 patients with equivalent non-diabetic renal impairment.
To our knowledge, this is the first large study comparing haemoglobin in patients with diabetic vs patients with nondiabetic renal impairment. This study for the first time also controls for other common contributing factors associated with anaemia in patients with renal impairment, e.g. ACEI use [16, 17] , secondary hyperparathyroidism [18] [19] [20] and iron deficiency.
The finding of lower haemoglobin in diabetic patients could have been due to: (1) relative deficiency of erythropoietin in patients with diabetes [14] ; (2) autonomic neuropathy associated with diabetes interfering with anaemia-sensing by the erythropoietin-producing cells in the kidney [21] [22] [23] ; (3) a lower baseline level but appropriate erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy [24] ; (4) damage to the erythropoietin-producing peri-tubular fibroblasts in patients with diabetes [25] ; and finally (5) chronic inflammation associated with diabetes [26] [27] [28] contributing to erythropoietin hypo-responsiveness. The retrospective nature of our study prevented measurement and analysis of serum erythropoietin levels or inflammatory markers like C-reactive protein in our cohort of patients. It should also be noted that up to 5% of patients with type 1 diabetes have associated coeliac disease [29] , which may contribute to anaemia. Since less than 25% of our diabetic patients were type 1, and ferritin levels were comparable, it is likely that even after correction for the projected incidence of coeliac disease, the haemoglobin levels were significantly lower in the diabetic than in the non-diabetic group. Possible weaknesses of the study are the retrospective study design and the inherent selection bias due to enrolment of only patients attending a tertiary referral renal service. Typically only patients with proteinuria±renal impairment and diabetes are referred to and followed up by nephrologists. Hence patients at the severe end of the diabetic nephropathy spectrum will be overrepresented. However, this bias will also be apparent in the non-diabetic renal impairment group, because regular follow-up is more likely in patients with more advanced renal impairment, where anticipatory intervention by nephrologists may be beneficial. Only a small number of patients with diabetes had diabetic nephropathy confirmed by renal histology. A clinical quartet of proteinuria, retinopathy, hypertension and diabetes±renal impairment are universally accepted as being diagnostic of diabetic kidney disease/diabetic nephropathy [30] , and these features have been used previously to define disease [31] . While some studies have suggested a high incidence of non-diabetic kidney disease in patients with diabetes and proteinuria [32] , others have not been able to replicate these findings [33] . The inclusion of retinopathy in our definition of diabetic nephropathy further strengthens the likelihood of this being the underlying pathology [34] . As uniformly quantified proteinuria data were not available, we were unable to assess the impact of this variable on haemoglobin levels.
In spite of the above-mentioned shortcomings, our study concludes that patients with diabetic kidney disease have significantly lower haemoglobin levels than patients with non-diabetic kidney disease. This relationship is not explained by differences in other common contributory factors to anaemia associated with renal impairment, implicating the presence of diabetes as an independent risk factor. A heightened awareness of this finding will help tighten surveillance for anaemia in patients with diabetes in general and diabetic patients with renal impairment in particular. Anaemia in patients with renal impairment contributes to considerable cardiovascular morbidity and mortality [35, 36] and in diabetic patients may speed progression to end-stage renal failure [37, 38] . Since proven, safe and effective treatment for anaemia associated with renal impairment is already widely available in the form of recombinant human erythropoietin, prospective trials of early erythropoietin intervention in patients with diabetic kidney disease are urgently required. Earlier correction of anaemia in this subset of patients may slow progression of renal impairment, reduce cardiovascular morbidity and improve patient survival.
